Giannis Mountzios, Sofia Lampaki, Georgia-Angeliki Koliou, Athanassios Vozikis, Ioannis Kontogiorgos, Panagiotis Papantoniou, Margarita-Ioanna Koufaki, Eleni Res, Anastasios Boutis, Athina Christopoulou, Nicoleta Pastelli, Anastasios Grivas, Gerasimos Aravantinos, Efthalia Lalla, Georgios Oikonomopoulos, Anna Koumarianou, Dionisios Spyratos, Dimitrios Bafaloukos, Georgios Rigakos, Pavlos Papakotoulas, George Fountzilas, Helena Linardou
Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line option for patients with advanced, EGFR-mutant non-small cell lung cancer (NSCLC). Afatinib, a second-generation irreversible EGFR-TKI, has been extensively used in Greece in this setting; however, real-world data regarding molecular epidemiology and financial implications of afatinib use are lacking. Materials and Methods: This was an observational, non-interventional, multicenter, retrospective cohort study, based on real-world data collected from the medical charts/records of patients treated with afatinib between 15/03/2015 and 25/06/2020 and were recorded on a web-based data capture system...
2021: Lung Cancer: Targets and Therapy